News >

Projecting the Impact of Immunotherapy in Advanced Ovarian Cancer

Caroline Seymour
Published: Friday, Aug 30, 2019

Rebecca C. Arend, MD

Rebecca C. Arend, MD
Unlike PARP inhibitors, which are showing extensive utility in a broader group of patients with advanced ovarian cancer, the impact of immunotherapy will likely be seen on a smaller scale. The onus, explained Rebecca C. Arend, MD, will lie in defining the patient subset in which this approach will provide the most benefit.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x